beta-estradiol stimulation of DNA synthesis requires different PKC isoforms in HepG2 and MCF7 cells

J Cell Physiol. 2001 Aug;188(2):170-7. doi: 10.1002/jcp.1105.

Abstract

The role exerted by protein kinase C (PKC) on estrogen-induced DNA synthesis has been investigated in hepatic and mammary gland cells, HepG2 and MCF7. 17-beta-estradiol stimulated DNA synthesis in HepG2 and MCF7 cells, maximal effect occurring at 10 nM. DNA synthesis stimulation was prevented by anti-estrogen ICI 182,780 and by inhibitor of PKC, Ro 31-8220. The rapid estradiol effects in MCF7 cells were determined by following the inositol trisphosphate (IP(3)) production and PKC-alpha membrane translocation. After estradiol treatment the increase of IP(3) production, prevented by anti-estrogen or by phospholipase C (PLC) inhibitor (neomycin), was present in MCF7 cells. In MDA cells, devoid of estrogen receptor, no effect was observed. The PKC-alpha presence on the membranes appeared unchanged in MCF7 cells. The PLC inhibitors, neomycin and U73,122, and PKC-alpha down regulator, phorbol 12-myristate 13-acetate (PMA), were able to prevent estradiol-induced DNA synthesis in hepatoma cells, but ineffective in mammary cells; wortmannin, an inhibitor of phosphoinositide 3-kinases (PI3-K), blocked DNA synthesis in both cell lines. These data show that beta-estradiol, via an estrogen receptor-mediated mechanism, activates more signal transduction pathways, and consequently different PKC isoforms in two responsive cell lines. In both cell lines PI3-K/PKC pathway is functional to the estrogen regulation of DNA synthesis, whereas in HepG2 cells the parallel involvement of the PLC/PKC-alpha pathway is present. The reported results indicate that the DNA synthesis stimulation by beta-estradiol requires the estrogen receptor and utilises one or more activated pathways in dependence on the cell equipment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androstadienes / pharmacology
  • Breast Neoplasms*
  • Carcinoma, Hepatocellular*
  • Cell Division / drug effects
  • Cell Division / physiology
  • Cell Membrane / enzymology
  • DNA Replication / drug effects*
  • DNA Replication / physiology
  • Enzyme Inhibitors / pharmacology
  • Estradiol / pharmacology*
  • Estrenes / pharmacology
  • Female
  • Humans
  • Indoles / pharmacology
  • Isoenzymes / antagonists & inhibitors
  • Isoenzymes / metabolism*
  • Liver Neoplasms*
  • Neomycin / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Protein Kinase C-alpha
  • Protein Synthesis Inhibitors / pharmacology
  • Pyrrolidinones / pharmacology
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Stimulation, Chemical
  • Thymidine / metabolism
  • Thymidine / pharmacology
  • Tritium
  • Tumor Cells, Cultured
  • Type C Phospholipases / metabolism
  • Wortmannin

Substances

  • Androstadienes
  • Enzyme Inhibitors
  • Estrenes
  • Indoles
  • Isoenzymes
  • Phosphodiesterase Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Synthesis Inhibitors
  • Pyrrolidinones
  • Tritium
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • Estradiol
  • PRKCA protein, human
  • Protein Kinase C
  • Protein Kinase C-alpha
  • Type C Phospholipases
  • Neomycin
  • Thymidine
  • Ro 31-8220
  • Wortmannin